Skip to content

Efficacy analysis of low intensity pulsed ultrasound combined with tamsulosin hydrochloride in the treatment of chronic prostatitis

Efficacy analysis of low intensity pulsed ultrasound combined with tamsulosin hydrochloride in the treatment of chronic prostatitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113742
Enrollment
Unknown
Registered
2025-12-02
Start date
2024-01-24
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic prostatitis

Interventions

A group:LIPUS
C group:LIPUS+ Tamsulosin Sustained-release Capsules
B group:Tamsulosin Sustained-release Capsules

Sponsors

The First People's Hospital of Pinghu
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic criteria for chronic prostatitis and is diagnosed as chronic prostatitis; 2.No other drugs or physical therapies, such as antibiotics or extracorporeal shock wave therapy, were received during the treatment process; 3.It has complete NIH-CPSI, SAS score and IIEF-5 score; 4.The symptoms have persisted for more than three months.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of tamsulosin hydrochloride allergy or renal insufficiency; 2. Patients with other urination symptoms that may cause prostatitis, such as benign prostatic hyperplasia, urinary tract infection, neurogenic bladder, etc. 3. Patients with other diseases that may cause pain or discomfort in the pelvic area, such as urinary calculi, cystitis, etc. 4. Abnormal perineal anatomy; 5. There is a coagulation disorder or thrombosis; 6. Have a history of pelvic surgery or radiotherapy.

Design outcomes

Primary

MeasureTime frame
NIH-CPSI Score;

Secondary

MeasureTime frame
SAS Score;IIEF-5 Score;

Countries

China

Contacts

Public ContactLiang Ke

The First People's Hospital of Pinghu

liangke771116@163.com+86 563 8582 2811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026